advanc
treatment
human
immunodefici
viru
hiv
acquir
immunodefici
syndrom
aid
transform
diseas
chronic
ill
result
individu
hiv
longer
life
expect
hiv
treat
earli
aggress
life
expect
approach
uninfect
individu
accord
center
diseas
control
prevent
cdc
annual
incid
hiv
remain
stabl
past
year
preval
hiv
individu
age
year
estim
although
number
illustr
dramat
increas
preval
hiv
sinc
larg
due
decreas
mortal
rate
associ
advent
antiretrovir
therapi
art
case
diarrhea
preart
era
due
infecti
pathogen
wide
believ
success
treatment
would
reduc
even
solv
problem
although
art
improv
surviv
qualiti
life
patient
hiv
even
decreas
incid
diarrhea
popul
diarrhea
remain
common
complaint
among
patient
continu
neg
impact
qualiti
life
furthermor
burden
diarrhea
hivinfect
popul
remain
high
caus
diarrhea
shift
toward
noninfecti
etiolog
one
survey
patient
receiv
art
report
symptom
diarrhea
previou
month
clinic
trial
data
would
suggest
event
may
due
effect
art
support
assert
us
histor
data
hivinfect
patient
cell
count
investig
demonstr
declin
infecti
diarrhea
year
correl
introduct
art
around
period
percentag
patient
noninfecti
diarrhea
increas
similar
trend
etiolog
differ
observ
countri
patient
take
art
versu
take
art
review
explor
explan
continu
burden
diarrhea
among
patient
hiv
discuss
diagnost
workup
provid
guidanc
hivassoci
noninfecti
diarrhea
treat
gutassoci
lymphoid
tissu
galt
largest
collect
lymphoid
tissu
human
bodi
gastrointestin
gi
tract
regularli
expos
complex
divers
assort
antigen
microbi
dietari
sourc
result
b
cell
gut
constantli
interact
antigen
induc
matur
plasma
cell
memori
cell
respect
persist
stimul
immun
system
lead
baselin
inflammatori
state
encourag
product
chemokin
adhes
molecul
mediat
movement
lymphocyt
mucos
tissu
gi
tract
target
phase
hiv
infect
effect
hiv
mucos
immun
system
appar
acut
infect
period
data
simian
model
simian
immunodefici
viru
patient
hiv
show
within
week
infect
vast
major
mucos
lamina
propria
lymphocyt
deplet
deplet
occur
well
decreas
cell
seen
peripheri
like
reflect
greater
express
cc
chemokin
receptor
type
function
primari
coreceptor
major
infect
hiv
strain
mucos
cell
express
chemokin
receptor
cell
support
entri
viru
state
physiolog
activ
respons
enhanc
hiv
replic
mucos
compart
subsequ
mucos
cell
deplet
despit
use
potent
antiretrovir
medic
hiv
persist
within
galt
lymphocyt
even
replet
cell
peripheri
thu
patient
chronic
hiv
infect
mucos
environ
contain
pauciti
cell
overpopul
cell
b
cell
give
wrong
impress
healthi
mucos
environ
microscop
level
etiolog
diarrhea
hivinfect
patient
divid
two
major
categori
noninfecti
infecti
treatment
hiv
improv
increas
peripher
cell
count
result
declin
risk
infect
associ
diarrhea
fig
indic
shift
noninfecti
etiolog
diarrhea
surpass
infecti
caus
noninfecti
diarrhea
defin
pathogenneg
diarrhea
includ
artassoci
diarrhea
gi
damag
relat
hiv
infect
ie
hiv
enteropathi
mani
caus
mirror
seen
gender
agematch
patient
without
hiv
infect
hiv
enteropathi
idiopath
form
diarrhea
observ
patient
hiv
absenc
infecti
sourc
characterist
histolog
featur
tabl
exact
mechan
chang
occur
gi
tract
unclear
hiv
postul
alter
signal
cellular
structur
may
lead
architectur
distort
sever
studi
demonstr
crypt
epitheli
prolifer
respons
hiv
infect
lead
increas
crypt
height
subsequ
crypt
cell
encroach
onto
villi
rel
decreas
villou
height
result
diarrhea
malabsorpt
studi
keat
colleagu
investig
monosaccharid
absorpt
patient
hiv
aid
demonstr
patient
diarrhea
signific
malabsorpt
monosaccharid
test
evid
malabsorpt
report
patient
pathogenneg
n
pathogenposit
n
diarrhea
suggest
malabsorpt
may
involv
hiv
enteropathi
well
pathogeninduc
diarrhea
hypothes
mechan
hiv
enteropathi
includ
decreas
transepitheli
electr
resist
decreas
sodiumdepend
glucos
absorpt
increas
intercellular
permeabl
hivinfect
cell
vitro
studi
demonstr
envelop
protein
hiv
induc
microtubul
disrupt
decreas
epitheli
resist
promot
calcium
signal
within
cell
affect
cytopath
chang
howev
effect
chlorid
secret
hiv
enteropathi
may
occur
stage
hiv
infect
acut
hiv
advanc
aid
data
suggest
hiv
may
capabl
infect
mucos
epitheli
cell
result
direct
effect
epitheli
cell
function
microscop
inflamm
may
mechanist
involv
hiv
enteropathi
hiv
rapidli
sever
deplet
mucos
cell
total
mucos
cell
popul
remain
larg
unchang
reflect
greater
mucos
infiltr
activ
cell
cell
prime
produc
proinflammatori
cytokin
chemokin
may
directli
damag
mucos
barrier
result
decreas
transepitheli
resist
diarrhea
shown
lead
malabsorpt
vitamin
bile
acid
monosaccharid
thu
hiv
enteropathi
also
specif
defin
physiolog
effect
small
bowel
function
diarrhea
advers
effect
art
proteas
inhibitor
seem
strongli
associ
diarrhea
tabl
mous
model
proteas
inhibitor
revers
transcriptas
inhibitor
found
significantli
increas
water
electrolyt
secret
intestin
lumen
vivo
rufo
colleagu
demonstr
proteas
inhibitor
gener
nelfinavir
particular
potenti
signal
muscarin
calciumdepend
receptor
intestin
cell
result
increas
chlorid
secret
lumen
studi
also
show
sodium
chlorid
concentr
stool
sampl
patient
hiv
take
nelfinavir
elev
consist
secretori
diarrhea
vitro
studi
bode
colleagu
found
proteas
inhibitor
induc
apoptosi
human
intestin
epithelium
compromis
barrier
function
cell
therebi
increas
water
secret
gut
lumen
wu
colleagu
also
investig
mechan
proteas
inhibitor
caus
diarrhea
found
lopinavir
ritonavir
notabl
amprenavir
induc
endoplasm
reticulum
dysfunct
intestin
epitheli
cell
expos
proteas
inhibitor
cell
found
decreas
alkalin
phosphatas
activ
therebi
increas
unfold
protein
accumul
defect
protein
cytosol
may
persist
activ
cell
unfold
protein
respons
specif
signal
pathway
aim
return
cell
protein
fold
function
back
normal
level
unfold
protein
decreas
cell
may
induc
apoptosi
function
bowel
disord
irrit
bowel
syndrom
ib
addit
condit
may
present
diarrhea
survey
conduct
veteran
affair
outpati
set
ib
common
hivposit
patient
compar
hivneg
patient
anoth
caus
noninfecti
diarrhea
small
intestin
bacteri
overgrowth
sibo
condit
increas
bacteria
small
intestin
lead
multipl
gi
symptom
includ
abdomin
bloat
discomfort
diarrhea
malabsorpt
condit
may
common
anatom
abnorm
motil
disord
appear
common
caus
diarrhea
hiv
cryptosporidiosi
caus
intracellular
pathogen
cryptosporidium
infect
cryptosporidium
parvum
common
caus
diarrhea
worldwid
estim
rate
case
cryptosporidi
infect
per
year
usa
risk
cryptosporidium
parvum
infect
greater
develop
countri
poor
sanit
spread
person
person
via
contamin
water
eg
drink
water
recreat
water
site
although
protozoa
caus
mild
selflimit
diseas
immunocompet
individu
manifest
sever
wateri
diarrhea
hivinfect
patient
also
occasion
lead
chronic
infect
profoundli
immunocompromis
cryptosporidium
parvum
lead
malabsorpt
syndrom
sever
dehydr
electrolyt
derang
protozo
infect
commonli
affect
patient
hiv
includ
microsporidia
isospora
cyclospora
less
commonli
toxoplasma
leishmania
speci
like
cryptosporidium
affect
small
intestin
lead
malabsorpt
diarrheal
ill
similarli
giardia
also
common
protozo
pathogen
hivinfect
immunocompet
host
infect
small
intestin
mucosa
entamoeba
histolytica
protozo
pathogen
caus
coliti
sever
immunocompromis
hivinfect
patient
rare
sever
circumst
lead
ulcer
hematochezia
even
toxic
megacolon
cytomegaloviru
cmv
common
viral
gi
pathogen
patient
aid
cmv
affect
entir
gi
tract
classic
lead
diarrhea
caus
coliti
character
rectal
bleed
abdomin
pain
system
sign
fever
weight
loss
hiv
infect
caus
diarrheal
ill
describ
multipl
virus
implic
diarrheal
pathogen
includ
adenoviru
coronaviru
herp
simplex
viru
rotaviru
noroviru
rare
fungi
report
caus
diarrhea
hivinfect
patient
infect
associ
endem
fungi
histoplasmosi
common
fungal
infect
requir
hospit
affect
part
gi
tract
caus
diarrhea
weight
loss
fever
mycobacterium
avium
complex
mac
typic
caus
diarrhea
patient
aid
profoundli
suppress
immun
system
ie
cell
count
symptom
vari
usual
reflect
system
natur
dissemin
infect
includ
fever
weight
loss
mac
usual
involv
small
intestin
howev
affect
entir
gi
tract
salmonella
shigella
campylobact
e
coli
bacteri
infect
gi
tract
present
diarrhea
usual
spread
food
water
contamin
patient
impair
immun
system
becom
asymptomat
carrier
pathogen
eg
shigella
campylobact
clostridium
difficil
investig
patient
recent
taken
antibiot
caus
pseudomembran
coliti
progress
toxic
megacolon
sever
infect
clostridium
difficil
common
patient
advanc
aid
cell
count
one
studi
evalu
incid
bacteri
diarrhea
patient
hiv
clostridium
difficil
common
identifi
culprit
account
episod
diarrhea
bacteri
pathogen
isol
overal
protozoa
fungi
mac
cmv
gi
infect
usual
seen
patient
hiv
immunocompromis
patient
note
earlier
improv
therapi
patient
infect
hiv
less
prone
develop
diarrhea
due
infecti
pathogen
prone
noninfecti
caus
basic
algorithm
diagnosi
evalu
diarrhea
patient
hiv
similar
examin
diarrhea
immunocompet
host
start
thorough
medic
histori
includ
durat
diarrhea
constitut
system
symptom
presenc
sever
abdomin
pain
question
characterist
diarrhea
eg
larg
versu
small
volum
infrequ
nocturn
versu
frequent
help
local
sourc
larg
small
intestin
narrow
differenti
diagnosi
fig
classic
diarrhea
patholog
small
intestin
present
volumin
wateri
occasion
associ
weight
loss
well
sign
symptom
malabsorpt
bloat
nausea
cramp
may
also
indic
small
intestin
sourc
diarrhea
larg
intestin
typic
character
smaller
frequent
bowel
movement
inflamm
rectum
anu
patient
may
describ
tenesmu
pain
defec
may
associ
hematochezia
care
review
medic
travel
histori
contact
ill
individu
recent
ingest
famili
histori
surgic
histori
social
histori
import
evalu
acut
chronic
diarrhea
patient
infect
hiv
physic
examin
medic
histori
patient
hiv
diarrhea
may
help
evalu
chronic
diarrhea
sever
ill
therebi
focu
differenti
diagnosi
nutrit
statu
assess
evalu
bitempor
wast
weight
chang
skin
turgor
mucos
dehydr
basic
vital
sign
orthostat
vital
sign
essenti
gaug
sever
patient
ill
degre
patient
volum
deplet
document
fever
may
import
clue
infecti
etiolog
though
absenc
fever
immunocompromis
host
rule
possibl
infect
gi
examin
may
reveal
tender
palpat
possibl
indic
pancreat
patholog
coliti
hepatosplenomegali
may
repres
mycobacteri
infect
hepat
fungal
malign
caus
diarrhea
rectal
examin
integr
import
may
reveal
sign
sexual
transmit
infect
bleed
tender
mass
may
help
establish
diagnosi
care
comprehens
examin
patient
essenti
evalu
sever
diseas
narrow
diagnosi
guid
manag
diagnost
evalu
may
also
aid
diagnosi
laboratori
test
includ
comprehens
metabol
panel
complet
blood
count
cell
differenti
blood
cultur
hiv
viral
load
cell
count
gaug
level
immun
suppress
stool
examin
includ
fecal
lactoferrin
fecal
leukocyt
fecal
calprotectin
fecal
occult
blood
clostridium
difficil
stool
cultur
well
three
separ
sampl
ova
parasit
infect
cryptosporidium
parvum
commonli
diagnos
microscop
identif
enzym
immunoassay
organ
stool
patient
also
made
biopsi
gi
tract
aspir
biliari
tree
endoscopi
diagnosi
giardia
made
immunoassay
stool
identifi
endoscop
biopsi
lumin
aspir
endoscopi
diagnosi
bacteri
infect
gi
tract
salmonella
made
stool
cultur
pathogen
identifi
workup
need
endoscop
examin
colonoscopi
biopsi
necessari
diagnosi
cmv
hsv
may
reveal
hemorrhag
coliti
ulcer
debat
whether
sigmoidoscopi
full
colonoscopi
would
benefici
one
colonoscopi
studi
n
show
nearli
patient
cmvassoci
coliti
diseas
local
cecum
howev
prospect
studi
compar
sigmoidoscopi
full
colonoscopi
show
sensit
sigmoidoscopi
enter
pathogen
full
colonoscopi
yield
small
increas
sensit
addit
case
cmvassoci
coliti
identifi
diagnosi
mac
infect
within
gi
tract
requir
endoscopi
may
identifi
ulcer
erythema
normal
mucosa
may
also
reveal
foami
macrophag
posit
cultur
via
biopsi
diagnosi
fungal
infect
may
made
histolog
biopsi
taken
endoscopi
colonoscopi
mucos
biopsi
also
help
diagnos
inflammatori
bowel
diseas
patient
neg
diagnost
result
diagnosi
noninfecti
diarrhea
made
treatment
infecti
diarrhea
outsid
scope
articl
section
focu
treatment
noninfecti
diarrhea
caus
diarrhea
identifi
patient
medic
review
evalu
iatrogen
caus
diarrhea
pharmacolog
option
treatment
noninfecti
diarrhea
patient
hiv
primarili
support
hydrat
via
intraven
oral
rout
replet
electrolyt
treat
underli
caus
possibl
import
therapi
patient
diarrhea
noninfecti
diarrhea
manag
modifi
art
control
symptom
medic
lifestyl
modif
howev
clinic
guidelin
patient
hiv
recommend
care
evalu
symptom
symptomat
manag
artrel
ae
eg
diarrhea
switch
art
support
care
eg
antidiarrh
gener
allow
continu
prescrib
art
therapi
howev
cessat
art
drug
holiday
gener
advis
manag
strategi
antidiarrh
medic
use
noninfecti
diarrhea
divid
sever
class
adsorb
antimotil
agent
antisecretori
agent
tabl
adsorb
drug
bind
bacteri
toxin
fluid
compound
intestin
improv
stool
consist
drug
categori
includ
bismuth
subsalicyl
kaolinpectin
attapulgit
aluminum
magnesium
silic
purifi
clay
data
use
adsorb
patient
hiv
limit
one
studi
efficaci
attapulgit
better
placebo
manag
diarrhea
antimotil
agent
includ
loperamid
diphenoxylateatropin
tinctur
opium
agent
act
upon
opioid
receptor
gut
slow
motil
decreas
peristalsi
increas
tone
larg
intestin
allow
greater
fecal
transit
time
therefor
longer
time
water
absorpt
antimotil
agent
diphenoxyl
cross
barrier
caus
central
effect
analog
opioid
agonist
prevent
abus
diphenoxyl
usual
sold
combin
agent
atropin
loperamid
cross
barrier
advers
effect
one
disadvantag
loperamid
may
interact
art
agent
ritonavir
saquinavir
limit
use
longterm
therapi
howev
loperamid
shown
small
trial
decreas
number
bowel
movement
patient
proteas
inhibitorinduc
diarrhea
use
combin
lowdos
diphenoxylateatropin
may
efficaci
treat
proteas
inhibitorinduc
diarrhea
howev
appear
combin
benefici
effect
patient
refractori
loperamid
therapi
although
studi
treatment
diarrhea
patient
hiv
tinctur
opium
consid
effect
loperamid
antimotil
agent
titrat
easili
tinctur
opium
may
consid
earli
treatment
algorithm
patient
sever
hivassoci
diarrhea
antisecretori
agent
octreotid
racecadotril
crofelem
directli
inhibit
secretori
process
within
enterocyt
mechan
action
octreotid
administ
subcutan
unclear
believ
alter
bind
vasoact
intestin
peptid
therefor
act
antimotil
antisecretori
agent
publish
data
conflict
efficaci
octreotid
treat
diarrhea
patient
aid
oral
racecadotril
enkephalinas
inhibitor
decreas
breakdown
endogen
gut
opioid
therebi
decreas
secret
water
electrolyt
gut
lumen
racecadotril
current
avail
usa
oral
administ
crofelem
dual
inhibitor
campstimul
cystic
fibrosi
transmembran
conduct
regul
cftr
calciumstimul
calciumactiv
chlorid
channel
cacc
gut
crofelem
minim
absorb
gi
drug
deriv
latex
croton
lechleri
tree
reportedli
use
amazonian
tribe
diarrheal
relief
crofelem
agent
approv
usa
symptomat
relief
noninfecti
diarrhea
patient
hiv
art
compar
placebo
crofelem
shown
random
doubleblind
placebocontrol
trial
openlabel
extens
significantli
reduc
symptom
noninfecti
diarrhea
patient
hiv
receiv
art
percentag
patient
wateri
stool
per
week
least
week
placebocontrol
phase
versu
respect
p
addit
crofelem
known
drug
interact
art
drug
minim
absorb
neg
impact
clinic
immun
paramet
eg
hiv
viral
load
cell
count
diarrhea
common
complic
hiv
infect
substanti
clinic
ramif
differenti
diagnosi
diarrhea
patient
hiv
broad
infect
histor
major
caus
diarrhea
patient
hiv
widespread
use
art
therapi
noninfecti
diarrhea
becom
burden
popul
medic
use
noninfecti
diarrhea
includ
antimotil
antisecretori
agent
includ
crofelem
shown
significantli
reduc
symptom
noninfecti
diarrhea
improv
treatment
noninfecti
diarrhea
like
improv
hiv
medic
adher
qualiti
life
